Company Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.
Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications.
The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | George Magrath M.B.A., M.D., M.S. |
Contact Details
Address: 37000 Grand River Ave., Suite 120 Farmington Hills, Michigan 48335 United States | |
| Phone | 248-681-9815 |
| Website | ocuphire.com |
Stock Details
| Ticker Symbol | OCUP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001228627 |
| CUSIP Number | 67577R102 |
| ISIN Number | US67577R1023 |
| Employer ID | 11-3516358 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard J. Rodgers M.B.A. | Interim President and Director |
| Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development and Operations and Secretary |
| Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance |
| George Magrath M.B.A., M.D., M.S. | Chief Executive Officer and Director |
| Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer |
| Joseph K. Schachle MBA | Chief Operating Officer |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific and Development Officer |
| Dr. Daniela C. Oniciu Ph.D. | Global Head of Research & Development, Chemistry and Product Development |
| Dr. Mitchell Brigell Ph.D. | Head of Clinical Development and Strategy |
| Chris Ernst | Global Head of QA and Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2024 | 8-K | Current Report |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 8, 2024 | 10-K | Annual Report |
| Mar 8, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 424B3 | Prospectus |
| Feb 16, 2024 | 8-K | Current Report |
| Jan 23, 2024 | EFFECT | Notice of Effectiveness |
| Jan 19, 2024 | UPLOAD | Filing |
| Jan 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |